Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors

Journal of Investigative Dermatology

Volumn 119, Issue 5, 2002, Pages 1059-1064

  Frotscher, Birgit ^a   Anton, Katrin ^a   Worm, Margitta ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allergy; Atopic dermatitis; CD40; Interleukin 4; Resiquimod

Indexed keywords

CD23 ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOGLOBULIN E; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PROTEIN; RESIQUIMOD;

ADOLESCENT; ALLERGIC RHINITIS; ALLERGY; ARTICLE; ATOPIC DERMATITIS; BLOOD; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DONOR; DRUG INHIBITION; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IN VITRO STUDY; INHIBITION KINETICS; MOLECULE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; SYNTHESIS;

EID: 0036452588     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.19531.x     Document Type: Article

References (36)

1. Adelroth E, Rak S, Haahtela T, et al: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106:253-259, 2000
2. Akdis CA, Blaser K: Immunologic mechanisms of specific immunotherapy. Allergy 54:31-32, 1999
3. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY: CD21 is a ligand for CD23 and regulates IgE production. Nature 358:505-507, 1992
4. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27:1131-1139, 1997
5. Bernstein DI, Harrison CJ, Tomai MA, Miller RL: Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis 183:844-849, 2001
6. Beutner KR, Tyring SK, Trofatter KF, et al: Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 42:789-794, 1998a
7. Beutner KR, Spruence S, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr: Treatment of genital warts with an immune response modifier (imiquimod). J Am Acad Dermatol 2:230-239, 1998b
8. Bishop GA, Ramirez LM, Baccam M, et al: The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol 208:9-17, 2001
9. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, Graber P, Aubry JP, Jeannin P, Plater-Zyberk C: Structure and functions of CD23. Int Rev Immunol 16:113-128, 1997
10. Carballido JM, Schols D, Namikawa R, Zurawski S, Zurawski G, Roncarolo MG, de Vries JE: IL-4 induces human B cell maturation and IgE synthesis in SCID-humice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist. J Immunol 155:4162-4170, 1995
11. Chen M, Griffith BP, Lucia HL, Hsuing GD: Efficacy of S-26308 against guinea pig cytomegalovirus. Antimicrob Agents Chemother 32:678-683, 1988
12. Coffman RL, Lebman DA, Rothman P: Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54:229-270, 1993
13. Corne J, Djukanovic R, Thomas L, et al: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. J Clin Invest 99:879-887, 1997
14. Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 140:4245-4252, 1988
15. Goldstein D, Hertzog P, Tomkinson E, et al: Administration of Imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Inf Dis 178: 858-861, 1998
16. Hanifin JM, Schneider LC, Leung DY, et al: Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 28:189-197, 1993
17. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI: Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 10:209-224, 1988
18. Hemmi H, Takeuchi O, Kawai T, et al: A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745, 2000
19. Hemmi H, Kaisho T, Takeuchi O, et al: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200, 2002
20. Kende M, Lupton HW, Canonico PG: Treatment of experimental viral infections with immunmodulators. Adv Biosci 68:51-63, 1988
21. Maitland JE, Maw R: An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. Int J STD-AIDS 11:268-270, 2000
22. Metzger WJ, Nyce JW: Oligonucleotide therapy of allergic asthma. J Allergy Clin Immunol 104:260-266, 1999
23. Miller RL, Imbertson LM, Reiter MJ, Schwartzmiller DH, Pecore SE, Gerster JF: Inhibition of herpes simplex virus infection in a guinea pig model by S-26308. ASM Interscience Conference. Antimicrob Agents Chemother. 235, 1985
24. Miller RL, Tomai MA, Harrison CJ, Bernstein DI: Immunomodulation as a treatment strategy for genital herpes: Review of the evidence. Int Immunopharmacol 2:443-451, 2002
25. Reinhold U, Kukel S, Brzoska J, Kreysel HW: Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 29:58-63, 1993
26. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA: Cytokine induction in mice by the immunmodulator imiquimod. J Leukocyte Biol 55:234-240, 1994
27. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME: A phase I clinical trial of imiquimod, an oral interferon inducer, administrated daily. Br J Cancer 74: 1482-1486, 1996
28. Sidky YA, Bryan GT, Weeks CE, Hatcher JM, Borden EC: Effects of treatment with an oral interferon inducer, imidazoquinolinamine (R-837), on the growth of mouse bladder carcinoma FCB. J Interferon Res 10:S123, 1990
29. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT: Inhibition of murine tumor growth by an interferon inducing imidazoquinoline. Cancer Res 52:3528-3533, 1992
30. Testermann TL, Gerster JF, Imbertson LM, et al: Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukocyte Biol 58:365-372, 1995
31. Te Velde AA, Rousset F, Peronne C, De Vries JE, Figdor CG: IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes. J Immunol 144:3052-3059, 1990
32. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ: The immune response modifiers imiquimod and R848 are potent activators of B lymphocytes. Cell Immunol 203:55-65, 2000
33. Vasilakos JP, Smith RM, Gibson SJ, et al: Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN. Cell Immunol 204:64-74, 2000
34. Wagner TL, Ahonen CL, Couture AM, et al: Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and Imiquimod. Cellular Immunol 191:10-19, 1998
35. Wheeler DJ, Parveen S, Pollock K, Williams RJ: Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI129471. Immunology 95:105-110, 1998
36. Xu L, Rothman P: IFN-gamma represses epsilon germline transcription and subsequently down-regulates switch recombination to epsilon. Int Immunol 6:515-521, 1994